Background: Biosimilar of Liraglutide developed in India has demonstrated non-inferiority in terms of safety, efficacy and quality compared to reference biologic. Basis this biosimilar of Liraglutide has been approved in India for management of T2DM. Data generated in Indian obese T2DM was further analyzed to see efficacy & safety with biosimilar of Liraglutide
Methods: This post hoc analysis assessed the efficacy & safety of Liraglutide biosimilar & reference biologic in obese T2DM Indians. Aim of this analysis was to assess mean change in glycemic parameters from baseline to week 24 in both the groups.
Results: Total 179 Obese patients (BMI 25 kg/m2 and above) were included in the post-hoc analysis. As shown in table 1 the change in HbA1c, FPG & PPBG at week 24 was significant compared to baseline in obese patients with biosimilar of Liraglutide & reference biologic (p<0.001). However, there was no significance between the change in glycemic parameters when intergroup comparison done for biosimilar of Liraglutide & reference biologic treatment.
Conclusion: Biosimilar of Liraglutide demonstrated comparable glycemic control with respect to the reference biologic in terms of reduction in HbA1c, FPG and PPBG from baseline to Week 24 in obese T2DM patients.
S.R. Joshi: Consultant; Twin Health, Marico, Franco Indian, Zydus Cadila, Glenmark Pharmaceuticals. Other Relationship; Novo Nordisk, Sanofi, MSD, Abbott Nutrition, Abbott, Biocon, Alkem, USV Private Limited, Boehringer-Ingelheim. H.V. Barkate: Employee; Glenmark Pharmaceuticals. A. Mane: None. A.U. Petare: Employee; Glenmark Pharmaceuticals. S.Y. Choudhari: Employee; Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Ltd.
Glenmark Pharmaceuticals Ltd.
